Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 6/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | AGXT | P21549 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 3/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26075399 | 0.90 | FEN1 (0.39) | FEN1ALOX5APACP1ESR1ESR2 | |
| SCHEMBL26075305 | 0.88 | DHODH (0.41) | ESR1ESR2DHODH | |
| SCHEMBL26075601 | 0.88 | AGXT (0.47) | PTGS2AGXTACP1DHODHLMNA | |
| SCHEMBL23590133 | 0.87 | DHODH (0.45) | FEN1ALOX5APESR1ESR2DHODH | |
| SCHEMBL26075890 | 0.87 | ESR1 (0.38) | ESR1ESR2DHODHLMNAMAPT | |
| SCHEMBL26075395 | 0.84 | ACP1 (0.39) | FEN1ALOX5APACP1ESR1ESR2 | |
| SCHEMBL26075379 | 0.83 | PTGS2 (0.44) | FEN1ALOX5APPTGS2LMNAMAPT | |
| SCHEMBL26075427 | 0.81 | LMNA (0.39) | FEN1ALOX5APACP1DHODHLMNA | |
| SCHEMBL26075335 | 0.81 | ACP1 (0.50) | FEN1ALOX5APACP1LMNAMAPT | |
| SCHEMBL26075950 | 0.80 | FEN1 (0.39) | FEN1ALOX5APACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | FEN1 3899/4885ALOX5AP 821/4885PTGS2 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.